Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

由于业绩不佳，GSK今年第二次下调了其年度疫苗收入指引。现在，该公司预计与2023年相比，疫苗板块收入将出现个位数的低百分比下降 。而在 ...

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（R ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

近日，在洛杉矶举行的2024年美国感染性疾病周（IDWeek）会议期间，默沙东和辉瑞分别展示了其针对呼吸道合胞病毒（RSV）的预防药物新数据，并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会，每年吸引 ...